Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider

Agata Burska(Nazarbayev University), Edward M Vital(University of Leeds)

RMD Open

March 1, 2023

10.1136/rmdopen-2022-002876

Cited by 24

Related Papers

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

|Annals of the Rheumatic Diseases|2023|913

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

|The Lancet Rheumatology|2019|478

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)

|The Lancet|2023|151

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

|Annals of the Rheumatic Diseases|2022|141